Previous 10 | Next 10 |
--News Direct-- While the industry has made great strides in cancer research and treatments, minority groups in the U.S. continue to bear a greater burden of cancers compared with others. Early detection and screenings are two ways to help address disparities and improve outcomes for th...
Alkermes (NASDAQ:ALKS) stock rose after the company's Q1 results beat analysts' estimates and it reiterated its financial expectations for 2022. Q1 total revenue rose +10.78% Y/Y to $278.5M. Net sales of proprietary products grew +31.78% Y/Y to ~$171.27M. "As we execute on our launc...
Gainers: Nutex Health (NUTX) +24%. Repligen (RGEN) +14%. Zentalis Pharmaceuticals (ZNTL) +14%. Alkermes (ALKS) +12%. Clever Leaves (CLVR) +8%. Losers: Molecular Partners (MOLN) -37%. Agile Therapeutics (AGRX) -28%. Immunome (IMNM) -1...
Alkermes press release (NASDAQ:ALKS): Q1 Non-GAAP EPS of $0.12 beats by $0.11. Revenue of $278.5M (+10.8% Y/Y) beats by $22.48M. Net sales of VIVITROL were $84.9 million, compared to $74.5 million for the same period in the prior year, representing an increase of approximately 14%. Net s...
Alkermes plc Reports First Quarter 2022 Financial Results PR Newswire — First Quarter Revenues of $278.5 Million Reflect Strong Performance of LYBALVI ® , ARISTADA ® and VIVITROL ® — — GAAP Loss per Share of ...
Alkermes (NASDAQ:ALKS) is scheduled to announce Q1 earnings results on Wednesday, April 27th, before market open. The consensus EPS Estimate is $0.01 (-90.9% Y/Y) and the consensus Revenue Estimate is $256.02M (+1.8% Y/Y). Over the last 2 years, ALKS has beaten EPS estimates 100% of the time ...
--News Direct-- Alcohol use disorder is a debilitating disease that impacts millions of people every day, and the stigma surrounding it prevents people from seeking help. This Alcohol Awareness Month, we encourage everyone to learn more. If you or someone you know is living with AU...
--News Direct-- April marks National Minority Health Month, a time for us to reflect on the work still needed to address and break down existing barriers that keep minority communities from seeking mental health care. While many factors can contribute to inequities, there are resources ...
Alkermes to Report First Quarter Financial Results on April 27, 2022 PR Newswire DUBLIN , April 20, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on We...
--News Direct-- In a recent article for Boston Business Journal , our head of Medical Affairs, Dr. Kanchan Relwani highlights the importance of patient-focused drug development and how we seek to incorporate the patient voice into all we do. About Alkermes Alkermes plc i...
News, Short Squeeze, Breakout and More Instantly...
Alkermes to Report Second Quarter Financial Results on July 24, 2024 PR Newswire DUBLIN , July 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, ...
2024-06-29 16:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-19 17:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...